A review found heterogeneous approaches and insufficient reporting in overviews on adverse events

被引:4
作者
Sachse, Thilo [1 ]
Mathes, Tim [1 ,2 ]
Dorando, Elena [1 ]
Hess, Simone [1 ]
Thurmann, Petra [3 ]
Schmiedl, Sven [3 ]
Kanji, Salmaan [4 ]
Lunny, Carole [5 ]
Thabet, Pierre [6 ]
Pieper, Dawid [1 ,7 ,8 ,9 ]
机构
[1] Witten Herdecke Univ, Inst Res Operat Med IFOM, Ostmerheimer Str 200, D-51109 Cologne, Germany
[2] Univ Med Ctr Gottingen, Inst Med Stat, Gottingen, Germany
[3] Helios Univ Hosp Wuppertal, Univ Witten Herdecke, Philipp Klee Inst Clin Pharmacol, Wuppertal, Germany
[4] Ottawa Hosp, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[5] Univ British Columbia, St Michaels Hosp, Knowledge Translat Program, Unity Hlth Toronto & Cochrane Hypertens Grp, Vancouver, BC, Canada
[6] Univ Ottawa, Hop Montfort, Ottawa, ON, Canada
[7] Brandenburg Med Sch Theodor Fontane, Inst Hlth Serv & Hlth Syst Res, Fac Hlth Sci Brandenburg, Rudersdorf, Germany
[8] Brandenburg Med Sch Theodor Fontane, Ctr Hlth Serv Res, Rudersdorf, Germany
[9] Witten Herdecke Univ, Inst Res Operat Med, D-51109 Cologne, Germany
关键词
Adverse drug-associated events; Evidence synthesis; Overview; Reporting quality; Methodological quality; Pharmacology; SYSTEMATIC REVIEWS; TOXICITY PHARMACOGENETICS; RISK; ASSOCIATION; MEDLINE; SAFETY;
D O I
10.1016/j.jclinepi.2022.08.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To investigate reporting and methodological characteristics of overviews on adverse (drug-associated) events (AEs) of pharmacological interventions. Study Design and Setting: We searched MEDLINE, Embase, Epistemonikos, and the Cochrane Database of Systematic Reviews from inception to May 17, 2021 for overviews exclusively investigating AEs of pharmacological interventions. We extracted general, reporting, and methodological characteristics and analyzed data descriptively. Results: We included 27 overviews, 70% of which were published in 2016 or later. The most common nomenclature in the title was "overview'' (56%), followed by "umbrella review'' (26%). The median number of included systematic reviews (SRs) in each overview was 15 (interquartile range 7-34). Study selection methods were reported in 52%, methods for data extraction in 67%, and methods for critical appraisal in 63% of overviews. An assessment of methodological quality of included SRs was performed in 70% of overviews. Only 22% of overviews reported strategies for dealing with overlapping SRs. An assessment of the certainty of the evidence was performed in 33% of overviews. Conclusion: To ensure methodological rigor, authors of overviews on AEs should follow available guidance for the conduct and reporting of overviews. (C) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:104 / 112
页数:9
相关论文
共 50 条
[31]   Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review [J].
Davies, Hannah G. ;
Thorley, Emma, V ;
Al-Bahadili, Rossul ;
Sutton, Natalina ;
Burt, Jessica ;
Hookham, Lauren ;
Karampatsas, Kostas ;
Lambach, Philipp ;
Munoz, Flor ;
Cutland, Clare L. ;
Omer, Saad ;
Le Doare, Kirsty .
VACCINE: X, 2024, 18
[32]   The reporting of adverse events associated with spinal manipulation in randomized clinical trials: an updated systematic review [J].
Gorrell, Lindsay M. ;
Brown, Benjamin T. ;
Engel, Roger ;
Lystad, Reidar P. .
BMJ OPEN, 2024, 14 (01)
[33]   Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews [J].
Mainou, Maria ;
Bougioukas, Konstantinos I. ;
Malandris, Konstantinos ;
Liakos, Aris ;
Klonizakis, Philippos ;
Avgerinos, Ioannis ;
Haidich, Anna-Betinna ;
Tsapas, Apostolos .
ANNALS OF HEMATOLOGY, 2024, 103 (08) :2681-2697
[34]   Reporting of adverse events associated with spinal manipulation in randomised clinical trials: an updated systematic review [J].
Gorrell, Lindsay M. ;
Brown, Benjamin T. ;
Engel, Roger ;
Lystad, Reidar P. .
BMJ OPEN, 2023, 13 (05)
[35]   A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor [J].
Pan, Yunyan ;
Wang, Yu ;
Zheng, Yifan ;
Chen, Jie ;
Li, Jia .
FRONTIERS IN PHARMACOLOGY, 2024, 15
[36]   Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System [J].
Min, Jae ;
Osborne, Vicki ;
Kowalski, Allison ;
Prosperi, Mattia .
DRUG SAFETY, 2018, 41 (03) :313-320
[37]   The reporting quality of acupuncture-related traumatic adverse events: a systematic review of case studies in Korea [J].
Kim, Sung-A ;
Lee, Ji-Su ;
Kim, Tae-Hun ;
Lee, Seunghoon ;
Lee, Jae-Dong ;
Kang, Jung Won .
BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2024, 24 (01)
[38]   Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios [J].
Ankrah, Daniel N. A. ;
Darko, Delese M. ;
Sabblah, George ;
Mantel-Teeuwisse, Aukje ;
Leufkens, Hubert M. G. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (01) :172-178
[39]   Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS database [J].
Zhang, Dongdong ;
Cai, Ying ;
Sun, Yixin ;
Zeng, Peiji ;
Wang, Wei ;
Wang, Wenhui ;
Cai, Chengfu .
JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2025, 18 (01)
[40]   Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) [J].
Li, Bing ;
Chen, Yan ;
Zhang, Yongyi ;
Qian, Mengying ;
Shan, Qing ;
Qian, Jiao ;
Guo, Jinmin .
EXPERT OPINION ON DRUG SAFETY, 2025,